Fulvia Ceccarelli

Pubblicazioni

Titolo Pubblicato in Anno
Clinical, histologic, and immunologic signatures of Small Fiber Neuropathy in Systemic Lupus Erythematosus JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM 2024
Application of SLE-DAS to assess subcutaneous belimumab efficacy in a cohort of systemic lupus erythematosus patients CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 2024
Caffeine improves systemic lupus erythematosus endothelial dysfunction by promoting endothelial progenitor cells survival RHEUMATOLOGY 2024
Belimumab 10 years later. how drug positioning has changed IMMUNOLOGIC RESEARCH 2024
Fibromyalgia, mood disorders and chronic damage are the main determinants of worse quality of life in systemic lupus erythematosus patients. results from a cross-sectional analysis. LUPUS 2024
PASSing to the patient side: early achieving of an acceptable symptom state in patients with rheumatoid arthritis treated with Janus kinase inhibitors. REUMATISMO 2024
Evidence of immune response to BNT162b2 COVID-19 vaccine in systemic lupus erythematosus patients treated with Belimumab LUPUS 2023
Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach CANCER IMMUNOLOGY, IMMUNOTHERAPY 2023
Membrane and Soluble CD137 in Systemic Lupus Erythematosus: Role as Biomarkers for Disease Activity JOURNAL OF IMMUNOLOGY RESEARCH 2023
Effectiveness of non-medical switch from adalimumab bio-originator to SB5 biosimilar and from ABP501 adalimumab biosimilar to SB5 biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational study CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 2023
Application of Machine Learning Models in Systemic Lupus Erythematosus INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 2023
Organ damage in Systemic Lupus Erythematosus patients: A multifactorial phenomenon AUTOIMMUNITY REVIEWS 2023
Rheumatic Diseases Development in Patients Treated by Anti-PD1 Immune Checkpoint Inhibitors: A Single-Centre Descriptive Study LIFE 2023
Early and late response and glucocorticoid-sparing effect of belimumab in patients with systemic lupus erythematosus with joint and skin manifestations. results from the belimumab in real life setting study-joint and skin (BeRLiSS-JS) JOURNAL OF PERSONALIZED MEDICINE 2023
Fragility fractures in lupus patients:. associated factors and comparison of four fracture risk assessment tools LUPUS 2023
Tapering and discontinuation of glucocorticoids in patients with rheumatoid arthritis treated with tofacitinib. SCIENTIFIC REPORTS 2023
Organ damage in systemic lupus erythematosus patients. a multifactorial phenomenon AUTOIMMUNITY REVIEWS 2023
Exercise-induced modulation of Interferon-signature. a therapeutic route toward management of systemic lupus erythematosus AUTOIMMUNITY REVIEWS 2023
KLRG1 is reduced on NK cells in SLE patients, inversely correlates with disease activity and is modulated by hydroxychloroquine in vitro LUPUS 2023
Belimumab decreases autophagy and citrullination in peripheral blood mononuclear cells from patients with systemic lupus erythematosus CELLS 2022

Progetti di Ricerca

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma